Skip to main content

Court rules in favor of Barr, Mylan's Alphapharm in patent suit


A subsidiary of Mylan won a patent infringement lawsuit regarding a generic version of Ortho-McNeil’s Razadyne tablets, Mylan announced Friday.

The United States District Court for the District of Delaware invalidated Janssen’s and Synaptech’s patent for the drug, known generically as galantamine tablets, USP, thus ruling in favor of Mylan subsidiary Alphapharm and Barr Laboratories.

The tablets are approved for treating mild to moderate dementia associated with Alzheimer’s disease and had sales of about $102 million during the 12 months ending June 30, according to Mylan.

Following the Food and Drug Administration’s Thursday approval Mylan’s tablets in 4-, 8- and 12-mg strengths, Mylan said it would immediately begin marketing them on behalf of Alphapharm through Mylan Pharmaceuticals, another subsidiary.

“This is yet another example of our continued and successful commitment to provide affordable medications to the patients who need them the most,” Mylan Vice Chairman and chief executive officer Robert Coury said.

This ad will auto-close in 10 seconds